Geron Corp. (GERN)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 886744 · fiscal year ends in Dec
Closing price $0.95 on 29 Oct 2026; 52-week range $0.95 to $1.95.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Market value
- $608.0M
- Cash
- $62.6M
- Debt
- $120.1M
- Debt to equity
- 0.55
- Shares outstanding
- 642.5M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2023 | 31 Dec 2023 | $237.0K | -$193.9M | -$184.1M | -$0.32 | -$168.6M | 10-K filed 28 Feb 2024 |
| FY2022 | 31 Dec 2022 | $596.0K | -$138.6M | -$141.9M | -$0.37 | -$127.8M | 10-K filed 16 Mar 2023 |
| FY2021 | 31 Dec 2021 | $1.4M | -$114.0M | -$116.1M | -$0.35 | -$95.8M | 10-K filed 10 Mar 2022 |
| FY2020 | 31 Dec 2020 | $253.0K | -$76.9M | -$75.6M | -$0.28 | -$67.1M | 10-K filed 11 Mar 2021 |
| FY2019 | 31 Dec 2019 | $460.0K | -$72.5M | -$68.5M | -$0.36 | -$44.2M | 10-K filed 12 Mar 2020 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $57.5M | -$16.7M | -$0.02 |
| Q1 FY2026 | 31 Mar 2026 | $51.8M | -$3.6M | -$0.01 |
| Q3 FY2025 | 30 Sep 2025 | $47.2M | -$18.4M | -$0.03 |
| Q2 FY2025 | 30 Jun 2025 | $49.0M | -$16.4M | -$0.02 |
| Q1 FY2025 | 31 Mar 2025 | $39.6M | -$19.8M | -$0.03 |
| Q3 FY2024 | 30 Sep 2024 | $28.3M | -$26.4M | -$0.04 |
| Q2 FY2024 | 30 Jun 2024 | $882.0K | -$67.4M | -$0.10 |
| Q1 FY2024 | 31 Mar 2024 | $304.0K | -$55.4M | -$0.09 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2023
| Segment | Revenue | Share |
|---|---|---|
| Royalties | $237.0K | 100.0% |
Company events
The newest 8-K filings of 294 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 28 Oct 2026 | 8-K | Other events | 8.01, 9.01 |
| 6 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 27 May 2026 | 8-K | Leadership change, Shareholder vote | 5.02, 5.07, 9.01 |
| 26 Mar 2026 | 8-K | Leadership change | 5.02 |
| 25 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 12 Jan 2026 | 8-K | Investor update | 7.01, 9.01 |
| 6 Jan 2026 | 8-K | Material agreement | 1.01 |
| 16 Dec 2025 | 8-K | Restructuring | 2.05 |
| 5 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 14 Oct 2025 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
| 6 Aug 2025 | 8-K | Leadership change | 5.02 |
| 6 Aug 2025 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 726 held.
| Filed | Form | Period |
|---|---|---|
| 28 Oct 2026 | 8-K | 28 Oct 2026 |
| 6 Aug 2026 | 8-K | 5 Aug 2026 |
| 5 Aug 2026 | S-8 | – |
| 5 Aug 2026 | 10-Q | 30 Jun 2026 |
| 27 May 2026 | 8-K | 20 May 2026 |
| 6 May 2026 | 10-Q | 31 Mar 2026 |
| 7 Apr 2026 | ARS | 31 Dec 2025 |
| 7 Apr 2026 | DEFA14A | – |
| 7 Apr 2026 | DEF 14A | 20 May 2026 |
| 26 Mar 2026 | 8-K | 25 Mar 2026 |
| 2 Mar 2026 | S-3ASR | – |
| 2 Mar 2026 | 10-K | 31 Dec 2025 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 30 Sep 2026 | Spiegel Robert J., Director | Took pay in stock | 6,351 | $1.23 | $7.8K | – | 1 Oct 2026 |
| 30 Jun 2026 | Spiegel Robert J., Director | Took pay in stock | 6,103 | $1.28 | $7.8K | – | 1 Jul 2026 |
| 31 Mar 2026 | Spiegel Robert J., Director | Took pay in stock | 5,243 | $1.49 | $7.8K | – | 1 Apr 2026 |
| 18 Feb 2026 | Robertson Michelle, EVP, CHIEF FINANCIAL OFFICER | Sale outside a trading plan | 9,855 | $1.94 | $19.1K | 17,645 | 19 Feb 2026 |
| 31 Dec 2025 | Spiegel Robert J., Director | Took pay in stock | 5,918 | $1.32 | $7.8K | – | 5 Jan 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 15 Dec 2025 | JAMES ZIEGLER, Officer | 20,000 | $27.4K | 15 Dec 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 14 Aug 2026 | RA Capital Management, L.P. | 13G amended | 9.9% | 66.5M |
| 7 Aug 2026 | STATE STREET CORPORATION | 13G | 5.6% | 35.9M |
| 15 May 2026 | Deep Track Capital, LP | 13G amended | 4.95% | 31.7M |
| 8 May 2026 | Soleus Capital Master Fund, L.P. | 13G amended | 6.5% | 41.5M |
| 26 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 3 Mar 2026 | Soleus Capital Master Fund, L.P. | 13G | 5.2% | 33.0M |
| 13 Feb 2026 | Deep Track Capital, LP | 13G amended | 5.09% | 32.5M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 74.6M | +0.98% | 9.87 |
| 30 Sep 2026 | 73.9M | -10.57% | 7.39 |
| 15 Sep 2026 | 82.6M | -2.91% | 6.69 |
| 31 Aug 2026 | 85.1M | +5.57% | 10.99 |
| 14 Aug 2026 | 80.6M | +4.94% | 5.81 |
| 31 Jul 2026 | 76.8M | +9.85% | 9.9 |
| 15 Jul 2026 | 69.9M | -12.84% | 6.75 |
| 30 Jun 2026 | 80.2M | +7.18% | 4.7 |
Funds that hold it
From each fund's latest Form 13F.
290 funds held it at 30 Jun 2026: 126 added and 61 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 49,115,571 | $62.9M | +1,795,792 |
| Ra Capital Management, L.P. | 42,809,751 | $54.8M | -20,961,615 |
| Soleus Capital Management, L.P. | 42,808,659 | $54.8M | +1,300,000 |
| State Street Corp. | 35,856,671 | $45.9M | +5,359,488 |
| Citadel Advisors LLC | 29,038,928 | $37.2M | +7,462,359 |
| Vanguard Capital Management LLC | 27,250,215 | $34.9M | +581,186 |
| Nantahala Capital Management, LLC | 24,450,000 | $31.3M | – |
| Clearbridge Investments, LLC | 19,648,853 | $25.2M | +28,533 |
| Eversept Partners, LP | 18,717,422 | $24.0M | -117,461 |
| Goldman Sachs Group Inc. | 16,633,368 | $21.3M | +5,456,777 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B